AI Transforms Healthcare Stocks in 2024: Revolutionizing Medicine Across the Globe

AI Transforms Healthcare Stocks in 2024: Revolutionizing Medicine Across the Globe
Dr. Essam Hamza, CEO of Treatment.com AI, comments: “The opportunity to partner with aiXplain, an organization at the heart of the AI evolution, and to be part of their evolving marketplace is fantastic. It helps fulfill our shared philosophies in the democratization of AI. Our goal is to have Treatment’s Global Library of Medicine (GLM) AI accessible to healthcare organizations and healthcare professionals alike, and aiXplain’s marketplace creates new opportunities for all parties.”
Healthcare AI related stocks to keep an eye on include Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM), Healwell Al Inc (TSE: AIDX), GE HealthCare Technologies Inc.’s (NASDAQ:GEHC) and VERSES AI Inc (OTCMKTS: VRSSF) (CBOE:VERS)

As we stand on the brink of technological revolutions, one of the most transformative forces is artificial intelligence (AI), reshaping the landscape of health and medicine. Health AI refers to the integration of AI technologies into various aspects of healthcare to improve outcomes, optimize efficiencies, and reduce costs. This burgeoning field is not just about incremental improvements, but about redefining what is possible in medicine. At its core, Health AI involves using machine learning algorithms and other forms of AI to process data, make decisions, and perform actions that typically require human intelligence. This includes a wide range of applications from diagnostic algorithms that read and interpret medical images, to robotic surgeries that execute procedures with precision surpassing human capabilities, to virtual health assistants that provide 24/7 support to patients.

In a significant stride toward equity and accessibility in healthcare, Treatment AI (OTCQB: TREIF) (CSE: TRUE) recently unveiled its latest initiatives, supported by both the federal government and the National Institute of Health (NIH). This comes alongside their strategic partnerships with aiXplain Inc. and Rush River Research, promising to transform healthcare technology through advanced AI solutions and substantial backing from influential institutions. Close to 600K shares exchanged hands on Wednesday on CSE: TRUE suggesting an increased interest from the trading and investing communities on WallStreet. 

Empowering Equity in Healthcare through AI

Treatment.com AI’s recent collaboration with Rush River Research in Minneapolis marks a pioneering venture to develop an AI-driven approach for collecting family medical histories that is culturally sensitive, particularly catering to African-American communities. Traditional methods often overlook critical details in non-traditional and blended family structures prevalent among racial and ethnic minorities, perpetuating disparities in prevention and risk management. This initiative, funded by the NIH, aims to rectify such inequities by refining how family health data is gathered and utilized.

NIH Funding and the Pursuit of Inclusive Technology

The NIH’s involvement through funding underscores the importance of developing healthcare technologies that not only address but actively counteract historical biases. The project’s approach involves engaging African American doctors and community members in focus groups, ensuring that the AI models developed by Treatment are informed by a broad spectrum of experiences and needs. This inclusive perspective is crucial for creating more equitable health outcomes and demonstrates Treatment’s commitment to diversity and precision in medical diagnostics.

Integration and Future Developments

As part of their broader efforts to enhance the Global Library of Medicine (GLM), Treatment.com AI and Rush River Research are not only developing this culturally sensitive prototype but are also planning for its future integration into electronic health records and online healthcare applications. This phase of development is supported by an expanded Phase 2 grant proposal to the NIH, aimed at commercializing the solution to broaden its impact and usability.

Dr. Kevin Peterson, Chief Medical Officer at Treatment, emphasizes the need for updated data collection methods: “Old data approaches inevitably reflect old biases. Treatment is confronting these issues by reinventing how data about families is collected and stored to reflect the realities of modern life.”

A Comprehensive Strategy for Healthcare Evolution

This initiative complements Treatment.com AI’s other major collaborations, including their partnership with aiXplain and the recent boost from federal AI funding initiatives announced by Prime Minister Justin Trudeau. Together, these efforts position Treatment.com AI at the forefront of a healthcare revolution, leveraging AI to enhance diagnostic accuracy, streamline healthcare processes, and make healthcare more inclusive.

The integration of GLM into aiXplain’s AI marketplace further ensures that the sophisticated tools developed by Treatment are accessible to a wider array of healthcare organizations, enhancing clinical outcomes across the board. The federal funding towards AI adoption in sectors like healthcare aligns perfectly with Treatment’s initiatives, promising a future where AI is a fundamental pillar of healthcare delivery.

Investment Opportunities and Market Implications

For traders and investors, the convergence of these strategic partnerships and federal support presents a potentially compelling opportunity. The healthcare AI market’s rapid growth, coupled with Treatment AI (OTCQB: TREIF) (CSE: TRUE)’s innovative approaches to overcoming historical disparities, sets the stage for potential, substantial returns on investment. Stakeholders are invited to partake in this transformative journey, as Treatment.com AI continues to push the boundaries of what is possible in the AI and healthcare industries.

Treatment AI (OTCQB: TREIF) (CSE: TRUE) collaborative efforts with Rush River Research and aiXplain, bolstered by NIH funding and federal backing, herald a transformative era in healthcare technology. These initiatives not only potentially promise to enhance the quality and efficiency of healthcare services but also emphasize the critical importance of inclusivity and equity in medical AI development. For investors and industry watchers, these developments signal a promising horizon filled with opportunities for growth and participation in an equitable healthcare future.

Healthcare AI related stocks to keep an eye on include Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM), Healwell Al Inc (TSE: AIDX), GE HealthCare Technologies Inc.’s (NASDAQ:GEHC) and VERSES AI Inc (OTCMKTS: VRSSF) (CBOE:VERS)

Disclaimer: This news article is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. The Bull Report is not-a-registered-investment-advisor. The Bull Report is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. The Bull Report accepts no liability for any losses arising from an investor’s reliance on the use of this material. Starting on Mar 15, 2024 The Bull Report has been compensated $47,000 per month for coverage of TRUE by Sunburst Capital Corp. The Bull Report and its affiliates or officers may purchase, hold, and sell shares of common stock of this stock, in the open market at any time without notice. The Bull Report will not update its purchases and sales of this stock in any future postings on The Bull Report’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *The Bull Report does not set price targets on securities. Never invest in a stock discussed on this website or in this email alert unless you can afford to lose your entire investment.

Sources: 

https://finance.yahoo.com/news/treatment-com-ai-welcomes-federal-120000957.html

https://www.cbc.ca/news/politics/federal-government-ai-investment-1.7166234

https://finance.yahoo.com/news/treatment-com-ai-funded-national-120000374.html

https://ca.finance.yahoo.com/news/healwell-ai-pentavere-achieves-validation-110000955.html

https://finance.yahoo.com/quote/TRUE.CN/

Media Contact
Company Name: TheBullReport
Contact Person: Ward Abbott
Email: [email protected]
City: Dallas
State: Texas
Country: United States
Website: https://www.thebullreport.com/


Posted

in

by

Tags: